---
title: "ARVN: First FDA-approved PROTAC and out-licensing drove record Q2 revenue and net income"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294814734.md"
description: "Achieved first FDA approval and out-licensing of a PROTAC degrader, driving a surge in revenue and net income for Q2 2026. Multiple clinical programs advanced, with key data readouts and a strong cash position supporting operations into 2028.Original document: Arvinas, Inc. [ARVN] SEC 8-K Current Report — Aug. 4 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-04T11:21:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294814734.md)
  - [en](https://longbridge.com/en/news/294814734.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294814734.md)
generator: "portal-rs"
---

# ARVN: First FDA-approved PROTAC and out-licensing drove record Q2 revenue and net income

Achieved first FDA approval and out-licensing of a PROTAC degrader, driving a surge in revenue and net income for Q2 2026. Multiple clinical programs advanced, with key data readouts and a strong cash position supporting operations into 2028.

Original document: Arvinas, Inc. \[ARVN\] SEC 8-K Current Report — Aug. 4 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [ARVN.US](https://longbridge.com/en/quote/ARVN.US.md)

## Related News & Research

- [Connor Clark & Lunn Investment Management Ltd. Invests $1.39 Million in Arvinas, Inc. $ARVN](https://longbridge.com/en/news/297417473.md)
- [Algert Global LLC Grows Stock Position in Arvinas, Inc. $ARVN](https://longbridge.com/en/news/297393652.md)
- [Arvinas grants 45,696 RSUs to newly hired employee under Nasdaq inducement award plan](https://longbridge.com/en/news/297691506.md)
- [Gyre Therapeutics outlines protein degrader pipeline, China commercial outlook in corporate presentation](https://longbridge.com/en/news/297654775.md)
- [GYRE: Global R&D engine advances novel degraders and DACs, funded by strong China commercial revenues](https://longbridge.com/en/news/297655933.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**